Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

Rhea-AI Summary

Indaptus Therapeutics (Nasdaq: INDP) has announced a $2.135 million registered direct offering and concurrent private placement. The company will issue 1,817,017 common shares along with unregistered warrants to purchase an equal number of shares. The combined purchase price is $1.175 per share, with warrants exercisable at $1.05 per share for five years. The proceeds will fund research and development activities, working capital, and general corporate purposes. The offering, expected to close around November 25, 2024, includes participation from a company officer and is being facilitated by Paulson Investment Company as the exclusive placement agent.

Positive

• Officer participation in the offering demonstrates internal confidence
• Secured immediate funding of $2.135 million for R&D activities
• Five-year warrant term provides long-term financing flexibility

Negative

• Offering price of $1.175 may represent a discount to market price
• Potential dilution from issuance of 1,817,017 new shares
• Additional dilution possible from warrant exercise of 1,817,017 shares

Insights

Financial Analyst

This micro-cap biotech's $2.135 million registered direct offering signals significant dilution, pricing at $1.175 per share with accompanying warrants at $1.05 - both well below recent trading levels. The inclusion of warrants for an equal number of shares (1,817,017) creates potential for further dilution. While the capital raise provides essential working capital, the pricing and structure suggest challenging market conditions for the company. The participation of an officer in the offering, while showing insider confidence, doesn't offset the dilutive impact. With a market cap of only about $10.6 million, this financing represents approximately 20% dilution to existing shareholders, not counting potential warrant exercises.

NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that it has entered into securities purchase agreements with investors, including an officer of Indaptus, for the issuance and sale of an aggregate of 1,817,017 of its shares of common stock. In a concurrent private placement, Indaptus has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 1,817,017 of its shares of common stock. The combined effective purchase price for each share of common stock and associated warrants is $1.175. The warrants will have an exercise price of $1.05 per share, will be immediately exercisable upon issuance and have a term of five years from the date of issuance. The closing of the offering is expected to take place on or about November 25, 2024, subject to the satisfaction of customary closing conditions.

Paulson Investment Company, LLC is acting as the exclusive placement agent in connection with the offering.

The gross proceeds to Indaptus from the offering are expected to be approximately $2.135 million, before deducting the placement agent’s fees and other offering expenses payable by Indaptus. Indaptus intends to use the net proceeds from the offering to fund its research and development activities and for working capital and general corporate purposes.

The shares of common stock were offered by the Company pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-267236), including a base prospectus, previously filed with the Securities and Exchange Commission (“SEC”) on September 1, 2022 and declared effective by the SEC on September 9, 2022. A final prospectus supplement and an accompanying base prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and accompanying base prospectus may also be obtained by contacting Donald A. Wojnowski Jr. of Paulson Investment Company, LLC at (646) 553-3691 or at dwojnowski@paulsoninvestment.com.

The warrants issued in the private placement and shares issuable upon exercise of such warrants were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Rule 506(b) of Regulation D promulgated thereunder, have not been registered under the Securities Act or applicable state securities laws and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements regarding the gross proceeds from the registered direct offering and private placement and anticipated use of the net proceeds. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Indaptus’ actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to risks related to market conditions. Other important factors discussed under the caption “Risk Factors” included in Indaptus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the SEC on November 12, 2024, its most recent Annual Report on Form 10-K filed with the SEC on March 13, 2024, and its other filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release. Indaptus undertakes no obligation to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except as required by applicable law.

Contact: investors@indaptusrx.com

Investor Relations Contact:
CORE IR
Louie Toma
louie@coreir.com

Media:
Cuttlefish Communications
Shira Derasmo
shira@cuttlefishpr.com
917-280-2497

FAQ

What is the size of Indaptus Therapeutics' (INDP) November 2024 offering?

Indaptus Therapeutics announced a $2.135 million registered direct offering and concurrent private placement on November 22, 2024.

What is the warrant exercise price for INDP's November 2024 offering?

The warrants have an exercise price of $1.05 per share and will be exercisable for five years from the date of issuance.

How many shares is Indaptus (INDP) issuing in the November 2024 offering?

Indaptus is issuing 1,817,017 common shares and warrants to purchase an additional 1,817,017 shares.

How will Indaptus Therapeutics (INDP) use the proceeds from the November 2024 offering?

Indaptus will use the proceeds to fund research and development activities, working capital, and general corporate purposes.